Breadcrumb

[A19-16] Daratumumab (multiple myeloma) - Addendum to Commission A18-66

Overview

Overview

Commission: Commission awarded on 2019-02-12 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A18-66  [PDF, 2 MB] (German version) Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A18-66] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-03-22 Addendum to Commission A18-66 (German version) 2 MBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Daratumumab (Darzalex) for the treatment of multiple myeloma

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close